Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPRI-CF113
- Development stage
- Phase 3
- Lead developer
- ASKA Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LPRI-CF113 is a small molecule drug candidate containing the synthetic progestin drospirenone, currently under development by ASKA Pharmaceutical for the treatment of dysmenorrhea. Drospirenone is unique among synthetic progestins because its pharmacological profile closely resembles natural progesterone, exhibiting potent progestogenic activity alongside antimineralocorticoid and antiandrogenic properties. In the treatment of dysmenorrhea, LPRI-CF113 works by suppressing ovulation and inhibiting the proliferation of the endometrium, which leads to a reduction in the synthesis of prostaglandins—the primary mediators of painful uterine contractions. As of early 2026, the compound is in Phase 1/2 clinical trials in Japan.
- Other names
- drospirenone
02
Targets
AR (Adrenergic receptors)MR (Mineralocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on LPRI-CF113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPRI-CF113.